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Background: After potentially curative resection of primary colorectal cancer, patients may bemonitored
by measurement of carcinoembryonic antigen and/or CT to detect asymptomatic metastatic disease
earlier.
Methods: A systematic review and meta-analysis was conducted to find evidence for the clinical effective-
ness of monitoring in advancing the diagnosis of recurrence and its effect on survival. MEDLINE (Ovid),
Embase, the Cochrane Library, Web of Science and other databases were searched for randomized com-
parisons of increased intensity monitoring compared with a contemporary standard policy after resection
of primary colorectal cancer.
Results: There were 16 randomized comparisons, 11 with published survival data. More intensive
monitoring advanced the diagnosis of recurrence by a median of 10 (i.q.r. 5–24) months. In ten of
11 studies the authors reported no demonstrable difference in overall survival. Seven RCTs, published
from 1995 to 2016, randomly assigned 3325 patients to a monitoring protocol made more intensive by
introducing new methods or increasing the frequency of existing follow-up protocols versus less invasive
monitoring. No detectable difference in overall survival was associated with more intensive monitoring
protocols (hazard ratio 0⋅98, 95 per cent c.i. 0⋅87 to 1⋅11).
Conclusion: Based on pooled data from randomized trials published from 1995 to 2016, the anticipated
survival benefit from surgical treatment resulting from earlier detection of metastases has not been
achieved.
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Introduction
A variety of monitoring strategies have been used in
patients who have had potentially curative surgery for pri-
mary colorectal cancer. Their aim has been to detect active
disease before it is symptomatic or clinically evident so
that further treatment can be instigated. Five random-
ized trials published from 1995 to 1998 were the sub-
ject of a systematic review and meta-analysis published
in 20021. Intensive follow-up was associated with signifi-
cantly earlier detection by a mean of 8⋅5months. The com-
bined risk ratio was 0⋅81 (95 per cent c.i. 0⋅70 to 0⋅94) in
favour of intensive follow-up. However, the authors found
that methods were poorly reported and concluded that
‘large trials are required to identify which components of
intensive follow up are most beneficial’. Since then, three
large trials2–4 of intensified monitoring have reported.
An updated search, systematic review and meta-analysis
have been undertaken to examine the effect of these
programmes on overall survival including all randomized
studies identified.
Methods
A systematic review of literature on follow-up strategies for
patients with colorectal cancer was conducted according to
the PRISMA guidelines5 and is registered in PROSPERO
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(CRD42015026835). This study was based on predefined
eligibility criteria and conducted according to a predefined
methodological approach.
Search strategy
An extensive search for published articles was conducted
in collaboration with a medical librarian. The electronic
databases of MEDLINE (Ovid), Embase, the Cochrane
Library andWeb of Science, Scopus, CINAHL (EBSCO),
PubMed publisher, Google Scholar, LILACS, SciELO
and ProQuest were searched. The searches identified four
index terms: large intestinal cancer, surgery, periodical
surveillance and mortality or survival. Appropriate the-
saurus terms (for MEDLINE, Embase and CINAHL) and
keywords in the title and/or abstract were combined by
Boolean logical operators, and adapted to the appropriate
syntax of each database. The reference lists of reviews and
included studies were cross-checked.
Selection of studies
Papers were screened by two independent investigators,
arbitrated by a third reviewer. Data were extracted from
studies reporting randomly assigned groups of patients in
surveillance protocols of differing intensity. Only studies
conducted in humans andwritten in English were included.
Studies with inadequate data on survival for meta-analysis
were retained for textual summaries of the design, findings
and conclusions.
Outcome measures
The primary outcome was the overall survival difference
between the existing monitoring strategy compared with a
more intensive monitoring strategy.
Quality control
Studies were checked independently for quality using the
Cochrane risk of bias tool6. The authors of all studies were
approached for further information7.
Data extraction
Data were extracted by one researcher and checked
independently by a second reviewer. A third inves-
tigator resolved any discrepancies. Patient numbers,
baseline characteristics, all-cause mortality, cancer-specific
mortality and recurrence rates were retrieved for each
study.
Potentially relevant studies
n = 13 987
Duplicates excluded
n = 6906
Articles for title/abstract screening
n = 7081
Excluded n = 7059
 No colorectal cancer n = 3067
 Other aspects of colorectal cancer n = 2758
 Case report n = 500
 Opinion/review n = 324
 Retrospective study n = 123
 Other language n = 110
 Conference/guidelines n = 109
 Before 1980 n = 68
Articles for full-text screening
n = 22 papers
n = 16 trials
Fig. 1 Flow chart showing selection of trials for review
Overall survival data were extracted as event rates
reported for more versus less intensive monitoring arms
of all randomized comparisons. Odds ratios (ORs) and
their variances were calculated. Hazard ratios (HRs)
were derived from Kaplan–Meier curves. The method
described by Williamson and colleagues8 was used to
estimate a logarithmic HR with corresponding variance
when the number of patients at risk was given at each
time point. If these data were not provided, the method of
Parmar et al.9 was used. The overall HR with 95 per cent
c.i. was estimated using an inverse variance-weighted
average10.
Statistical analysis
Review Manager (RevMan) for Windows® version 5.3
(Nordic Cochrane Centre, Cochrane Collaboration,
Copenhagen, Denmark) was used for meta-analysis.
Funnel plots were used to investigate publication bias.
Heterogeneity among the included studies was analysed by
means of the I2 measure11. A random-effects meta-analysis
was performed after exclusion of trials with a high risk
of bias.
ORs were also used to summarize observed effects, and a
random-effects logistic regression model was used to pro-
vide an overall estimate of an effect for subsets of studies
defined by the chosen method of enhanced detection. Sub-
group analyses of outcome were performed to account for
different diagnostic tests used during follow-up in differ-
ent randomized trials. Studies were grouped as follows: any
site of recurrence; endoscopically detected recurrence; or
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Table 1 Studies excluded from meta-analysis
Trial Start End Tests No. of centres
No. of patients
randomized Reason for exclusion
Barillari et al.18 1980 1990 Colonoscopy 1 212 Inadequate survival data
Schoemaker et al.21 1984 1990 CT 1 325 Potential lack of allocation
concealmentColonoscopy
Secco et al.23 1988 1996 CEA 1 337 Reviewers could not reconcile
conclusions with randomized
groups
Colonoscopy
Ultrasonography
COLOFOL28 2006 2011 CEA 24 2571 Results not yet published
CT
CEAwatch31 2010 2012 CEA 11 3223 No outcome data reported
CEA, carcinoembryonic antigen.
Table 2 Details of the seven trials included in meta-analysis
Trial Start End Tests* No. of centres
No. of patients
randomized Authors’ conclusion
CEASL30 1982 1993 CEA 58 216† ‘… highly unlikely that any survival advantage
would be demonstrated for patients
undergoing second-look surgery’
Ohlsson et al.17 1983 1986 Endoscopy 2 107 ‘Intense follow-up … did not prolong survival
in this study’CT
CEA
Pietra et al.22 1987 1990 CEA 1 207 ‘Our data support use of an intense follow-up
plan after primary resection of large-bowel
cancer, at least in patients with rectal
cancer’
Ultrasonography
CT
Chest X-ray
Colonoscopy
Mäkelä et al.16 1988 1990 CEA 1 106 ‘Earlier detection of recurrent carcinoma by
intensified follow-up does not lead to
increased re-resectability or improved
5-year survival’
Chest X-ray
CT
Rodriguez -Moranta
et al.2
1997 2001 CEA 3 259 ‘there was no difference in the probability of
overall survival’Colonoscopy
CT
Ultrasonography
Chest X-ray
GILDA4 1998 2006 CEA 41 1228 ‘early diagnosis of cancer recurrence is not
associated with overall survival benefit’Colonoscopy
Chest X-ray
Ultrasonography
FACS3 2003 2009 CEA 39 1202 ‘The number of deaths was not significantly
different in the combined intensive
monitoring groups vs the minimum
follow-up group’
CT
*There were more tests, more frequent tests, or both in the group with more intensive monitoring. †If the carcinoembryonic antigen (CEA) level was
raised according to study criteria, patients were randomized to have this revealed to the clinical team or not.
the clinical setting of follow-up. Sensitivity analyses were
performed to identify studies that were estimated to have a
high risk of bias.
Meta-analysis was undertaken and forest plots were con-
structed for all trials that reached the criteria for inclusion.
Since the previous meta-analysis calling for large trials1,
there have been three large multicentre trials, published
in 2006, 2014 and 20162–4 relating to policies of earlier
detection of patients suitable for the growing practice of
metastasectomy12–14. The analysis was repeated in this
subset of trials.
Results
Among 7081 publications, there were 22 relevant
articles2–4,15–33 describing 16 randomized comparisons
(Fig. 1). Text summaries of all 16 randomized trials are
provided in Appendix S1 (supporting information). Five
studies were excluded because there were no survival data
available for analysis28,31 or they had high risk of bias18,21,23
(Table 1). The remaining 11 studies provided data on
overall survival suitable for meta-analysis and, of these,
seven2–4,16,17,22,30 included methods that allowed detection
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Fig. 2 Forest plot showing hazard ratios for death in seven randomized comparisons of more and less intensive follow-up from which
hazard ratios could be derived. An inverse-variance random-effects model was used to produce an overall estimated hazards ratio.
Hazard ratios are shown with 95 per cent confidence intervals. The studies are ordered according to the year of the start of the
inclusion. CEASL is dominant because the weight of the study is dependent on the follow-up time, number of events and number of
patients in each treatment arm. The Kaplan–Meier curve in CEASL is plotted up to 25 years. The point estimate in favour of more
intensive monitoring in studies by Rodriguez-Moranta et al.2 and Pietra and colleagues22 was attributed by the authors to detection by
endoscopy and successful treatment of recurrent rectal carcinoma
Reference
Death rate
CEASL30
Ohlsson et al.17
Pietra et al.22
Mäkelä et al.16
Rodriguez-Moranta et al.2
91 of 108
15 of 53
28 of 104
23 of 52
21 of 127
113 of 615
164 of 901
455 of 1960
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22 of 54
43 of 103
27 of 54
27 of 132
105 of 613
48 of 301
360 of 1365
9·4
7·6
12·6
8·3
11·3
27·4
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1·22 (0·60, 2·47)
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0·51 (0·29, 0·92)
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Test for overall effect: Z = 0·77, P = 0·44
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Fig. 3 Forest plot showing odds ratios for death in seven randomized comparisons of more and less intensive follow-up. A
Mantel–Haenszel random-effects model was used to produce an overall estimated odds ratio. Odds ratios are shown with 95 per cent
confidence intervals
Table 3 Details of single-centre trials confined to endoscopic methods of monitoring
Trial Start End Tests No. of patients Authors’ conclusions
Kjeldsen et al.20 1983 1994 Colonoscopy 597 ‘no improvement in overall survival or in cancer-related
survival’
Wang et al.27 1995 2001 Colonoscopy 326 There was higher detection of asymptomatic recurrence and
more operations but the authors concluded that more
intensive colonoscopy ‘did not improve overall survival’
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Table 4 Risk of bias
Reference Randomization method Allocation concealment Incomplete outcome assessment Selective reporting
CEASL30 Low Low Low Low
Ohlsson et al.17 Unclear Unclear Low Low
Pietra et al.22 Unclear Unclear Low Low
Rodriguez-Moranta et al.2 Low Low Low Low
Mäkelä et al.16 Unclear Unclear Low Low
GILDA4 Unclear Low Low Low
FACS3 Unclear Unclear Low Low
Kjeldsen et al.20 Unclear Unclear High* Low
Wang et al.27 Unclear Low Unclear Low
Wattchow et al.24 Unclear Low Low Low
Augestad et al.25 Low Low Low Low
Schoemaker et al.21 Low High† Unclear Low
Secco et al.23 High‡ Unclear High§ Low
CEAwatch31 Low Low Low Low
*Groups not balanced (290 : 307); drop-outs may not be included in assessment. †Cards not in envelopes; groups not balanced (167 : 158). ‡Method
unclear; groups not balanced (108 : 84 and 84 : 61). §Patients excluded from survival rather than censored if lost to follow-up. COLOFOL has not reported
so cannot be assessed; the methods of assignment were not described by Barillari et al.18, and this did not appear to be a true randomized comparison.
Table 5 Cancer recurrence rates and difference in time to detection in RCTs of monitoring strategies following potentially curative
resection of colorectal cancer
Recurrence (%)
Reference Recruitment Methods tested* Intensive Control
Detection advance
(months)
CEASL30 1982–1993 CEA –† –† 11
Ohlsson et al.17 1983–1986 CEA, CT, endoscopy 4
Kjeldsen et al.20 1983–1984 Endoscopy 26 26 9
Mäkelä et al.16 1988–1990 CT 42 39 5
Wang et al.27 1995–2001 Endoscopy 8 11 13
GILDA4 1998–2006 CT, endoscopy, liver ultrasonography 15 13 6
Wattchow et al.24 1998–2001 Setting: surgeon- or GP-led 2
FACS3
CEA 2003–2009 CEA 22 14 24
CT 2004–2009 CT 20 14 30
CEA and CT 2005–2009 CEA, CT 17⋅5 14 24
*Only tests that were not the same in the two groups. †Only a minority of patients meeting the stringent carcinoembryonic antigen (CEA) criteria were
randomized, so detection was similar in both randomized groups and effectively 100 per cent.
Table 6 All-cause mortality rates in randomized trials
All-cause mortality
Intensive follow-up
Less intensive
follow-up
CEASL30 91 of 108 (84⋅3) 88 of 108 (81⋅5)
Mäkelä et al.16 23 of 52 (44) 27 of 54 (50)
Ohlsson et al.17 15 of 53 (28) 22 of 54 (41)
Kjeldsen et al.20 88 of 290 (30⋅3) 100 of 307 (32⋅6)
Pietra et al.22 28 of 104 (26⋅9) 43 of 103 (41⋅7)
Schoemaker et al.21 43 of 167 (25⋅7) 55 of 158 (34⋅8)
Secco et al.23 73 of 192 (38⋅0) 81 of 145 (55⋅9)
GILDA4 113 of 615 (18⋅4) 105 of 613 (17⋅1)
Rodriguez-Moranta et al.2 21 of 127 (16⋅5) 27 of 132 (20⋅5)
Wattchow et al.24 32 of 76 (42) 25 of 81 (31)
Wang et al.27 42 of 165 (25⋅5) 50 of 161 (31⋅1)
Augestad et al.25 1 of 55 (2) 4 of 55 (7)
FACS3,34 164 of 901 (18⋅2) 48 of 301 (15⋅9)
CEAwatch31 n.r. n.r.
COLOFOL28 n.r. n.r.
Total 734 of 2905 (25⋅3) 675 of 2272 (29⋅7)
Values in parentheses are percentages. n.r., Not reported.
Table 7 Local recurrence rates in randomized trials
Local recurrence
Intensive follow-up
Less intensive
follow-up
CEASL30 n.r. n.r.
Mäkelä et al.16 12 of 52 (23) 11 of 54 (20)
Ohlsson et al.17 11 of 53 (21) 8 of 54 (15)
Kjeldsen et al.19,20 49 of 290 (16⋅9) 42 of 307 (13⋅7)
Pietra et al.22 20 of 104 (19⋅2) 26 of 103 (25⋅2)
Schoemaker et al.21 7 of 167 (4⋅2) 11 of 158 (7⋅0)
Secco et al.23 41 of 192 (21⋅4) 35 of 145 (24⋅1)
GILDA4 36 of 615 (5⋅9) 32 of 613 (5⋅2)
Rodriguez-Moranta et al.2 11 of 127 (8⋅7) 13 of 132 (10⋅1)
Wattchow et al.24 n.r. n.r.
Wang et al.27 10 of 165 (6⋅1) 12 of 161 (7⋅5)
Augestad et al.25 6 of 55 (11) 8 of 55 (15)
FACS3,34 35 of 901 (3⋅9) 6 of 301 (2⋅0)
CEAwatch31 31 of 316 (9⋅8) 13 of 1182 (1⋅1)
COLOFOL28 n.r n.r.
Total 269 of 3037 (8⋅9) 217 of 3265 (6⋅6)
Values in parentheses are percentages. n.r., Not reported.
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Table 8 Distant recurrence rates in randomized trials
Distant recurrence
Intensive follow-up
Less intensive
follow-up
CEASL30 32 of 108 (29⋅6) n.r.
Mäkelä et al.16 10 of 52 (19) 10 of 54 (19)
Ohlsson et al.17 9 of 53 (17) 12 of 54 (22)
Kjeldsen et al.19,20 34 of 290 (11⋅7) 48 of 307 (15⋅6)
Pietra et al.22 15 of 104 (14⋅4) 21 of 103 (20⋅4)
Schoemaker et al.21 n.r. n.r.
Secco et al.23 38 of 192 (19⋅8) 47 of 145 (32⋅4)
GILDA4 59 of 615 (9⋅6) 42 of 613 (6⋅9)
Rodriguez-Moranta et al.2 20 of 127 (15⋅7) 19 of 132 (14⋅4)
Wattchow et al.24 n.r. n.r.
Wang et al.27 n.r. n.r.
Augestad et al.25 3 of 55 (5) 4 of 55 (7)
FACS3,34 39 of 901 (4⋅3) 18 of 301 (6⋅0)
CEAwatch31 n.r. n.r.
COLOFOL28 n.r. n.r.
Total 259 of 2497 (10⋅4) 221 of 1764 (12⋅5)
Values in parentheses are percentages. n.r., Not reported.
of metastases (Table 2, Figs 2 and 3). Two studies20,27 were
confined to endoscopic examination following more or
less intensive protocols (Table 3). Two studies24,25 followed
the same protocol in each arm but were administered in
hospital by a specialist or in a general practice setting.
Detailed protocols for investigations used for monitoring
and their frequency are summarized in Appendix S2 (sup-
porting information).
Quality of studies: risk of bias
Three studies were found to have a high risk of bias
in at least one domain (Table 4). Blinding of participants
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Fig. 5 Funnel plot of studies included in meta-analysis. Reference
numbers are shown
and personnel (performance bias) was not possible and
so there is a remaining risk of bias. Blinding of outcome
assessment (detection bias) is not relevant for the main
outcome measure, which is death/survival.
Effectiveness of more intensive monitoring
in advancing detection
For studies in which the time difference in detection was
given (9 of 16) the advance in diagnosis was 2–30 months,
with a median of 10 (i.q.r. 5–24) months (Table 5).
Reference
Death rate
Kjeldsen et al.20
Endoscopically detected
recurrence
Setting
Wang et al.27
88 of 290
42 of 165
26 of 131
100 of 307
50 of 161
36 of 136
66·2
33·8
Wattchow et al.24
Augestad et al.26
25 of 76
1 of 55
32 of 81
4 of 55
92·0
8·0
100·0
0·90 (0·64, 1·27)
0·76 (0·47, 1·23)
Total
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Test for overall effect: Z = 1·18, P = 0·24
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Test for overall effect: Z = 1·13, P = 0·26
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Fig. 4 Forest plot for death in two studies in which the difference in monitoring was confined to endoscopy, and two studies for which
the difference was between a hospital/specialist setting and a general practice setting. A Mantel–Haenszel random-effects model was
used to produce an overall estimated odds ratio. Odds ratios are shown with 95 per cent confidence intervals
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Fig. 6 Subset analysis of three large multicentre RCTs published in 2006, 2014 and 2016, which included 80⋅9 per cent of all patients in
the full systematic review. A random-effects inverse-variance model was used to produce an overall estimated hazards ratio. Hazard
ratios are shown with 95 per cent confidence intervals
Main outcome measure: effectiveness in improving
survival
The numbers of randomized patients and the numbers
of all detection events and deaths are given in Tables 6–8.
The principal result derives from the meta-analysis of HRs
based on trials from which these could be estimated. The
summary HR estimate was 0⋅98 (95 per cent c.i. 0⋅87 to
1⋅11), with no evidence of significant heterogeneity (I2 = 14
per cent) (Fig. 2).
The meta-analysis of simple ORs for death based on the
same seven studies is shown in Fig. 3; the summary OR for
death was 0⋅91 (95 per cent c.i. 0⋅71 to 1⋅16). ORs were
derived from the percentage of deaths in each arm at the
time of reporting, whereas the HR gives an estimate of
the overall relative survival, which is more relevant when
considering a time-to-event endpoint.
A meta-analysis of ORs for death is also shown for two
studies in which the difference in monitoring was confined
to endoscopy, and two studies for which the difference was
between a hospital/specialist setting and a general practice
setting (Fig. 4).
There is a residual possibility of publication bias as
demonstrated in the asymmetry of the forest plot for the
main analysis (Fig. 2) and the funnel plot (Fig. 5). Because
of the proportion of the weight accredited by RevMan to
CEASL (Carcino-Embryonic Antigen Second Look), and
because in this study themonitoring was solely by CEA and
not CT, a sensitivity analysis was performed after exclusion
of CEASL. This did not alter the conclusion (HR 0⋅92,
0⋅76 to 1⋅36)
The three trials reporting from 2006 to 2016 were larger,
multicentre, better quality studies and contributed 2689
(80⋅9 per cent) of the 3325 patients included in the overall
meta-analysis (Fig. 2). The summary estimated HR from
a meta-analysis of these trials was 1⋅05 (0⋅87 to 1⋅27)
(Fig. 6).
Discussion
The question addressed by this systematic review is
whether follow-up strategies involving more intensive
monitoring, with more frequent investigation and/or
additional methods of detection, lead to an improvement
in overall survival. Meta-analyses of the ORs and derived
HRs from seven RCTs including 3325 patients showed no
survival benefit from successively intensified monitoring
policies. The authors of ten2–4,16,17,20,24,25,27,30 of the 11
trials reported no survival benefit from more intensive
monitoring. This could have been due to lack of power,
but the meta-analysis is consistent with the findings of
individual studies. Three studies4,24,26 that reported out-
comes on quality of life found no differences with respect
to this outcome.
A random-effects model and, where possible, HRs were
used to quantify outcomes, as the outcomes of interest
occur over time. Owing to data limitations, ORs were
used for some comparisons. Where it was possible to
do both analyses, there was no difference in the con-
clusion. A limitation of this systematic review is that
publication bias may have affected the observed out-
comes as unpublished data, abstracts and presentations
were not included. However, consideration of this pos-
sible bias would likely make a survival benefit even less
plausible.
Intensive follow-up was reported to show significantly
improved survival by the authors of only one study22. It
was attributed to reappearance of treatable residual disease
after resection of rectal (as opposed to colonic) cancer.
In exploratory subset analyses, other studies2,4 showed a
survival difference in favour of more intensive monitoring
benefit where local recurrence of rectal cancer was found
endoscopically.
Earlier meta-analyses1,35 suggested a favourable effect on
survival. This was not found in the present meta-analysis,
which included larger and methodologically more robust
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trials reported in the past couple of years. These showed
poorer survival in the more intensively screened groups,
although the results were not significant individually. The
survival results of this updatedmeta-analysis show no bene-
fit. Although not statistically significant, the point estimates
consistently suggest an adverse effect on survival. What
these later RCTs have in common is that they were multi-
centre studies run from trial centres. It is possible that
the commitment of physicians involved in follow-up has
made a difference to outcomes in smaller institutional stud-
ies. Many of these patients will have had individualized
treatment including systemic chemotherapy, but no over-
all benefit from monitoring and earlier detection has been
shown in the meta-analysis. This analysis gives a coher-
ent and trustworthy, but disappointingly negative, mes-
sage about the hoped-for survival benefit of intensification
of active monitoring after primary resection of colorectal
cancer.
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S. Mokhles, F. Macbeth, V. Farewell, F. Fiorentino, N. Williams, R. N. Younes et al.
Editor’s comment
Cancer is a frightening word that brings uncertainty to patients’ lives and those of their loved ones. It is our role
to dispel fear, establish trust, and deliver realistic expectations for the future. Tests give confidence to both parties if
sensitive, specific, and comfortable, as well as cost-effective and generalizable. Clinical assessment, quality colonoscopy,
serum carcinoembryonic antigen testing, and baseline CT fulfil all those targets at diagnosis. Repetition of scans every
6–12 months is in doubt if the findings presented here do not represent immortal time bias or other anomaly. If so,
then we understand pitifully little of the biological interplay between host and disease that evade the (evidently) crude
instruments of this age.
Cancer outcomes improved with specialized surgery, multidisciplinary management, and molecular-targeted ther-
apy, so it is counterintuitive that earlier identification of metastatic disease does not improve survival. Intensive surveil-
lance should prolong disease-specific survival by bringing forward the date of diagnosis and by rendering the disease
burden easier to manage. Far from being the bleak nihilism some will choose to see, this paper will stimulate evolution
(not cessation) of surveillance and metastasis-directed healthcare. It challenges us to determine how to follow patients
optimally, to whom to offer intensive monitoring, and to better define the molecular complexity of tumour-immune
interfaces. Fear of the unknown is a burden we have allowed patients to shoulder while we peer over the horizon of
their personal voyage. If you are not alarmed that modern colorectal cancer care is suboptimal after reading this paper,
please reflect on it again.
D. C. Winter
Editor, BJS
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